PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
22436698-11	2012	Moreover, the selective 5-HT(2C) receptor antagonist RS-102221 abrogated the actions of DOI in suppressing the M-current.	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	53-62	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	24-41
12097814-6	2002	Administration of the selective 5-HT2C antagonist RS 102221 (1.0 and 2.0 mg/kg) considerably increased the time spent by males at the partition (p < 0.001) and, at the dose of 2.0 mg/kg, increased plasma testosterone levels (p < 0.01).	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	50-59	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	32-38
20488736-7	2010	Intrathecal administration of the 5-HT2C receptor antagonist, 8-[5-2,4-dimethoxy-5-(4-trifluoromethylphenylsulphonamido)phenyl-5-oxopentyl]-1,3,8-triazaspiro[4,5]decane-2,4-dione (RS-102221: 30 mug) did not alter the mechanical threshold.	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	180-189	5-hydroxytryptamine receptor 2C	Rattus norvegicus	34-40
20488736-8	2010	Intrathecal pretreatment with RS-102221 (10 and 30 mug) reduced the antiallodynic effects of the highest dose of 5-HT2C agonists.	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	30-39	5-hydroxytryptamine receptor 2C	Rattus norvegicus	113-119
18339223-5	2008	Experiments1-4 revealed that systemic administration of the 5-HT2C antagonist RS 102221 (2 mg/kg) selectively decreases compulsive lever-pressing, whereas systemic administration of the 5-HT2A antagonist MDL11,939(0.2-5 mg/kg) or of the 5-HT2A/2C agonist DOI (0.05-5 mg/kg) did not have a selective effect on this behaviour.	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	78-87	5-hydroxytryptamine receptor 2C	Rattus norvegicus	60-66
27511837-10	2016	Amongst the subtype selective 5HT2 antagonists, only RS 102221 (5HT2C-selectively) counteracted the rise in action potential firing elicited by 5HT.	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	53-62	5-hydroxytryptamine receptor 2C	Rattus norvegicus	64-69
9225287-0	1997	RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist.	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	0-9	5-hydroxytryptamine receptor 2C	Rattus norvegicus	48-54
9225287-4	1997	As part of an effort to further explore the function of 5-HT2C receptors, we have developed a selective 5-HT2C receptor antagonist, RS-102221 (a benzenesulfonamide of 8-[5-(5-amino-2,4-dimethoxyphenyl) 5-oxopentyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione).	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	132-141	5-hydroxytryptamine receptor 2C	Rattus norvegicus	56-62
9225287-4	1997	As part of an effort to further explore the function of 5-HT2C receptors, we have developed a selective 5-HT2C receptor antagonist, RS-102221 (a benzenesulfonamide of 8-[5-(5-amino-2,4-dimethoxyphenyl) 5-oxopentyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione).	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	132-141	5-hydroxytryptamine receptor 2C	Rattus norvegicus	104-110
9225287-4	1997	As part of an effort to further explore the function of 5-HT2C receptors, we have developed a selective 5-HT2C receptor antagonist, RS-102221 (a benzenesulfonamide of 8-[5-(5-amino-2,4-dimethoxyphenyl) 5-oxopentyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione).	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	167-253	5-hydroxytryptamine receptor 2C	Rattus norvegicus	104-110
9225287-8	1997	Consistent with its action as a 5-HT2C receptor antagonist, daily dosing with RS-102221 (2 mg/kg intraperitoneal) increased food-intake and weight-gain in rats.	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	78-87	5-hydroxytryptamine receptor 2C	Rattus norvegicus	32-38
9225287-10	1997	It is concluded that RS-102221 is the first selective, high affinity 5-HT2C receptor antagonist to be described.	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	21-30	5-hydroxytryptamine receptor 2C	Rattus norvegicus	69-75
34815296-6	2021	Intra-lOFC infusions of the 5-HT2C antagonist RS 102221 reduced risky choice in animals that showed a preference for the risky options of the rGT at baseline.	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	46-55	5-hydroxytryptamine receptor 2C	Rattus norvegicus	28-34
34675083-5	2021	Activation of the endogenous 5-HT receptors on pinealocytes evoked an intracellular Ca2+ rise that was blocked by RS-102221, an antagonist of 5-HT2C receptors.	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	114-123	5-hydroxytryptamine receptor 2C	Homo sapiens	142-148
31883927-6	2020	The reversal of somatic hyperalgesia and visceral hypersensitivity by VPA in FS rats was blocked by intrathecal administration of the selective 5-HT2C receptor antagonist RS-102221 (30 mug/10 muL) 30 min after each VPA injection.	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	171-180	5-hydroxytryptamine receptor 2C	Rattus norvegicus	144-150
35092569-5	2022	Subsequent spinal administration of RS102221 to inhibit 5-HT2C receptors or SR57227 to activate 5-HT3 receptors reversed the analgesic effect of SAHA under both conditions.	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	36-44	5-hydroxytryptamine receptor 2C	Rattus norvegicus	56-62
29369737-7	2018	Furthermore, contractions elicited by MK-212 (5-HT2C agonist) was blocked by RS-102221 (5-HT2C antagonist), although noncompetitively.	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	77-86	5-hydroxytryptamine receptor 2C	Bos taurus	46-52
29369737-7	2018	Furthermore, contractions elicited by MK-212 (5-HT2C agonist) was blocked by RS-102221 (5-HT2C antagonist), although noncompetitively.	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	77-86	5-hydroxytryptamine receptor 2C	Bos taurus	88-94
27686964-9	2016	Either RS-102221 or terguride reduced the increments in lung water contents, grading of lung fibrosis, lung tumor necrosis factor-alpha (TNF-alpha), transforming growth factor-beta1 (TGF-beta1) and vascular endothelial growth factor (VEGF) levels in lung injury and fibrosis-induced by bleomycin.	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	7-16	tumor necrosis factor	Rattus norvegicus	108-135
27686964-9	2016	Either RS-102221 or terguride reduced the increments in lung water contents, grading of lung fibrosis, lung tumor necrosis factor-alpha (TNF-alpha), transforming growth factor-beta1 (TGF-beta1) and vascular endothelial growth factor (VEGF) levels in lung injury and fibrosis-induced by bleomycin.	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	7-16	tumor necrosis factor	Rattus norvegicus	137-146
27686964-9	2016	Either RS-102221 or terguride reduced the increments in lung water contents, grading of lung fibrosis, lung tumor necrosis factor-alpha (TNF-alpha), transforming growth factor-beta1 (TGF-beta1) and vascular endothelial growth factor (VEGF) levels in lung injury and fibrosis-induced by bleomycin.	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	7-16	transforming growth factor, beta 1	Rattus norvegicus	149-181
27686964-9	2016	Either RS-102221 or terguride reduced the increments in lung water contents, grading of lung fibrosis, lung tumor necrosis factor-alpha (TNF-alpha), transforming growth factor-beta1 (TGF-beta1) and vascular endothelial growth factor (VEGF) levels in lung injury and fibrosis-induced by bleomycin.	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	7-16	transforming growth factor, beta 1	Rattus norvegicus	183-192
27686964-9	2016	Either RS-102221 or terguride reduced the increments in lung water contents, grading of lung fibrosis, lung tumor necrosis factor-alpha (TNF-alpha), transforming growth factor-beta1 (TGF-beta1) and vascular endothelial growth factor (VEGF) levels in lung injury and fibrosis-induced by bleomycin.	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	7-16	vascular endothelial growth factor A	Rattus norvegicus	198-232
27686964-9	2016	Either RS-102221 or terguride reduced the increments in lung water contents, grading of lung fibrosis, lung tumor necrosis factor-alpha (TNF-alpha), transforming growth factor-beta1 (TGF-beta1) and vascular endothelial growth factor (VEGF) levels in lung injury and fibrosis-induced by bleomycin.	8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione	7-16	vascular endothelial growth factor A	Rattus norvegicus	234-238